Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Lineage Cell Therapeutics (LCTX) Long-Term Deferred Tax (2016 - 2025)

Lineage Cell Therapeutics' Long-Term Deferred Tax history spans 7 years, with the latest figure at $5.8 million for Q4 2025.

For Q4 2025, Long-Term Deferred Tax rose 2016.48% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $5.8 million, up 2016.48%, while the annual FY2025 figure was $5.8 million, 2016.48% up from the prior year.
Long-Term Deferred Tax reached $5.8 million in Q4 2025 per LCTX's latest filing, up from $273000.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $5.8 million in Q4 2025 to a low of $273000.0 in Q4 2024.